General MedicationsINTRAVITREALStandard
VABYSMO
FARICIMAB-SVOA
Standard Dose
120MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview VABYSMO is listed in Drugs@FDA under application 761235 (BLA).
Review priority: N/A Marketing status: Prescription Active ingredient FARICIMAB-SVOA Form and strength INJECTABLE; INTRAVITREAL - 120MG/ML Sponsor GENENTECH INC Submission history Latest submission status date: 2024-07-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview VABYSMO is listed in Drugs@FDA under application 761235 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient FARICIMAB-SVOA Form and strength INJECTABLE; INTRAVITREAL - 120MG/ML Sponsor GENENTECH INC Submission history Latest submission status date: 2024-07-03 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.